Could a leukemia drug slow Alzheimer's? small study tests safety
NCT ID NCT02947893
First seen Feb 14, 2026 · Last updated Jun 17, 2026 · Updated 18 times
Summary
This study tested a low dose of nilotinib, a drug used for leukemia, in 37 people with mild to moderate Alzheimer's disease. The goal was to see if the drug is safe and can reach the brain to affect proteins linked to Alzheimer's, like tau and amyloid. Participants took the drug or a placebo daily for a period, and researchers monitored side effects and changes in spinal fluid and brain scans. The study was small and focused on safety, so it does not prove the drug works for Alzheimer's.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Georgetown University Medical Center
Washington D.C., District of Columbia, 20057, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.